CO5640124A2 - Combinacion de un antagonista de mglur2 y un inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos - Google Patents
Combinacion de un antagonista de mglur2 y un inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicosInfo
- Publication number
- CO5640124A2 CO5640124A2 CO06006378A CO06006378A CO5640124A2 CO 5640124 A2 CO5640124 A2 CO 5640124A2 CO 06006378 A CO06006378 A CO 06006378A CO 06006378 A CO06006378 A CO 06006378A CO 5640124 A2 CO5640124 A2 CO 5640124A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkoxy
- alkyl
- nrand
- fluoro
- halogen
- Prior art date
Links
- 229940124596 AChE inhibitor Drugs 0.000 title abstract 4
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 230000001154 acute effect Effects 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 230000001684 chronic effect Effects 0.000 title abstract 2
- 101150016175 Grm2 gene Proteins 0.000 title 1
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- -1 pyrrole-1-yl Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 abstract 1
- AZIZBYRGIGKTLW-UHFFFAOYSA-N 1,4-diazepin-2-one Chemical compound O=C1C=NC=CC=N1 AZIZBYRGIGKTLW-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1.- Una composición comprendiendo un inhibidor de AChE y un antagonista mGluR2.2.- Una composición comprendiendo un inhibidor de AChE y un derivado de dihidro-benzo[b] [1, 4] diazepin-2-ona.3.- Una composición comprendiendo un inhibidor de AChE y un compuesto de formula I en donde X es un enlace simple o un grupo etinodiilo;Y es -CH= o =N-;R1 es, en el caso que X sea un enlace simple, hidrógeno, ciano, halógeno, alquilo-(C1-C7), alcoxi-(C1-C7), fluoroalquilo - (C1-C7), fluoroalcoxi-(C1-C7), pirrol-1-ilo o fenilo, que está sin sustituir o sustituido por uno o dos sustituyentes seleccionados del grupo constituido por halógeno, alquilo-(C1-C7) o fluoroalquilo-(C1-C7); o R1 es, en el caso que X sea un grupo etinodiilo, fenilo, que está sin sustituir o sustituido por uno o dos sustituyentes seleccionados del grupo constituido por halógeno, alquilo- (C1-C7), o fluoroalquilo-(C1-C7);R2 es hidrógeno, alquilo-(C1-C7), alquenilo-(C2-C7), alcoxi-(C1-C7), halógeno, -NRAND#39R", pirrolidin-1-ilo, piperidin-1-ilo, morfolin-4-ilo, fluoro-alquilo-(C1-C7), fluoro-alcoxi-(C1-C7), o alcoxi-(C1-C7) - (etoxi)m; en donde m es 1, 2, 3, o 4; RAND#39 y R" son cada uno independientemente hidrógeno, alquilo-(C1-C7), o cicloalquilo-(C3-C7); y R3 es un heterociclo aromático de seis miembros conteniendo 1 a 3 átomos de nitrógeno o un piridina-N-óxido, cuyos anillos están sin sustituir o sustituidos por uno o dos sustituyentes seleccionados del grupo constituido por halógeno, fluoro-alquilo-(C1-C7), fluoro-alcoxi-(C1-C7), ciano, amino, alquilamino-(C1-C7), dialquilamino- (C1-C7), alcoxi-(C1-C7)-alquilamino-(C1-C7), (C1-C7)-hidroxialquilamino- (C1-C7), -(CH2)n-C(O) -OR", - (CH2)n-C(O)-NRAND#39R", (CH2)n-SO2-NRAND#39R", -(CH2)n-C(NH2)=NRAND#39R", hidroxilo, alcoxi(C1-C7), alquiltio- (C1-C7), cicloalquilo- (C3-C7) y alquilo(C1-C7), que está opcionalmente sustituido por fluoro, NRAND#39R", hidroxilo, alcoxi-(C1-C7), pirrolidin-1-ilo, azetidin-1-ilo, ciano o carbamoiloxi, en donde n es 0, 1, 2, 3 o 4; y RAND#39 y R" tienen los significados especificados anteriormente;o una sal de adición farmacéuticamente aceptable de los mismos en la fabricación de un medicamento para prevenir o tratar un trastorno neurológico agudo y/o crónico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03016968 | 2003-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5640124A2 true CO5640124A2 (es) | 2006-05-31 |
Family
ID=34130033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO06006378A CO5640124A2 (es) | 2003-07-25 | 2006-01-24 | Combinacion de un antagonista de mglur2 y un inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7235547B2 (es) |
| EP (1) | EP1651234B1 (es) |
| JP (1) | JP5005343B2 (es) |
| KR (1) | KR100764330B1 (es) |
| CN (1) | CN1856312A (es) |
| AR (1) | AR045926A1 (es) |
| AT (1) | ATE374030T1 (es) |
| AU (1) | AU2004262897B9 (es) |
| BR (1) | BRPI0412919A (es) |
| CA (1) | CA2532347C (es) |
| CO (1) | CO5640124A2 (es) |
| DE (1) | DE602004009195T2 (es) |
| DK (1) | DK1651234T3 (es) |
| ES (1) | ES2293287T3 (es) |
| HR (1) | HRP20070552T3 (es) |
| IL (1) | IL173131A (es) |
| MX (1) | MXPA06000705A (es) |
| MY (1) | MY138394A (es) |
| NO (1) | NO20060328L (es) |
| NZ (1) | NZ544719A (es) |
| PL (1) | PL1651234T3 (es) |
| PT (1) | PT1651234E (es) |
| RU (1) | RU2357734C2 (es) |
| SI (1) | SI1651234T1 (es) |
| TW (1) | TW200524614A (es) |
| WO (1) | WO2005014002A1 (es) |
| ZA (1) | ZA200600693B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US20050222175A1 (en) * | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US7488736B2 (en) * | 2004-05-17 | 2009-02-10 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| US7407966B2 (en) * | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| US7576211B2 (en) * | 2004-09-30 | 2009-08-18 | Epix Delaware, Inc. | Synthesis of thienopyridinone compounds and related intermediates |
| US7598265B2 (en) * | 2004-09-30 | 2009-10-06 | Epix Delaware, Inc. | Compositions and methods for treating CNS disorders |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP1942879A1 (en) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | アンジオテンシン調節による神経新生 |
| KR20090064418A (ko) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| US8114894B2 (en) * | 2008-12-03 | 2012-02-14 | Nanotherapeutics, Inc. | Bicyclic compounds and methods of making and using same |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US8541404B2 (en) * | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| RU2472475C2 (ru) * | 2010-04-20 | 2013-01-20 | Учреждение образования "Белорусский государственный медицинский университет" (УО БГМУ) | Способ комбинированного лечения глаукомной оптической нейропатии |
| AR093077A1 (es) | 2012-10-23 | 2015-05-20 | Hoffmann La Roche | ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS |
| JP2017513844A (ja) | 2014-04-23 | 2017-06-01 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 知的障害の処置のためのｍＧｌｕ２／３アンタゴニスト |
| CN112462047B (zh) * | 2020-11-13 | 2023-02-07 | 北京元恩生物技术有限公司 | 一种尼卡巴嗪检测试剂盒及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663318A (en) * | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| JP2002518480A (ja) * | 1998-06-22 | 2002-06-25 | ニューロサーチ、アクティーゼルスカブ | ５−又は８−ブロモイソキノリン誘導体の製造方法 |
| US6194403B1 (en) * | 1999-09-09 | 2001-02-27 | Unitech Pharmaceuticals, Inc. | Tacrine derivatives for treating Alzheimer's disease |
| DK1224174T3 (da) * | 1999-10-15 | 2004-01-26 | Hoffmann La Roche | Benzodiazepinderivater |
| NZ518037A (en) * | 1999-10-15 | 2004-04-30 | F | Benzodiazepine derivatives useful as metabotropic glutamate receptors |
| CA2310926C (en) * | 2000-04-03 | 2002-10-15 | Janssen Pharmaceutica N.V. | A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease |
| EP1203584A1 (en) | 2000-10-13 | 2002-05-08 | M.D.M. S.r.l. | Cholinergic precursor (in particular choline alfoscerate) associated with an acetylcholinesterase inhibitor (such as rivastigmine, donepezil) |
| US6500972B2 (en) * | 2001-01-03 | 2002-12-31 | Chinese Petroleim Corp. | Synthesis of TMBQ with transition metal-containing molecular sieve as catalysts |
| US6500955B1 (en) * | 2001-02-02 | 2002-12-31 | National Institute Of Pharmaceutical Education And Research | One pot synthesis of [2,8-Bis (trifluoromethyl)-4-quinolinyl]-2-pyridinylmethanone, a mefloquine intermediate |
| WO2002083662A2 (en) * | 2001-04-09 | 2002-10-24 | Fuji Photo Film Co., Ltd. | Azo compounds and process of producing the same and novel intermediate compounds used in the process of producing azo compounds |
| HRP20030792A2 (en) * | 2001-04-12 | 2005-10-31 | F. Hoffmann - La Roche Ag | DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II |
| KR100566178B1 (ko) * | 2001-04-12 | 2006-03-29 | 에프. 호프만-라 로슈 아게 | ｍＧｌｕＲ2 길항물질 Ｉ로서의디하이드로-벤조[ｂ][1,4]디아제핀-2-온 유도체 |
| US6949542B2 (en) * | 2002-02-06 | 2005-09-27 | Hoffman-La Roche Inc. | Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
-
2004
- 2004-07-17 PL PL04741126T patent/PL1651234T3/pl unknown
- 2004-07-17 DK DK04741126T patent/DK1651234T3/da active
- 2004-07-17 EP EP04741126A patent/EP1651234B1/en not_active Expired - Lifetime
- 2004-07-17 JP JP2006521458A patent/JP5005343B2/ja not_active Expired - Fee Related
- 2004-07-17 CA CA2532347A patent/CA2532347C/en not_active Expired - Fee Related
- 2004-07-17 PT PT04741126T patent/PT1651234E/pt unknown
- 2004-07-17 AU AU2004262897A patent/AU2004262897B9/en not_active Ceased
- 2004-07-17 BR BRPI0412919-9A patent/BRPI0412919A/pt not_active Application Discontinuation
- 2004-07-17 AT AT04741126T patent/ATE374030T1/de active
- 2004-07-17 MX MXPA06000705A patent/MXPA06000705A/es active IP Right Grant
- 2004-07-17 KR KR1020067001762A patent/KR100764330B1/ko not_active Expired - Fee Related
- 2004-07-17 NZ NZ544719A patent/NZ544719A/xx unknown
- 2004-07-17 SI SI200430524T patent/SI1651234T1/sl unknown
- 2004-07-17 WO PCT/EP2004/008020 patent/WO2005014002A1/en not_active Ceased
- 2004-07-17 RU RU2006105721/15A patent/RU2357734C2/ru not_active IP Right Cessation
- 2004-07-17 ES ES04741126T patent/ES2293287T3/es not_active Expired - Lifetime
- 2004-07-17 CN CNA2004800278083A patent/CN1856312A/zh active Pending
- 2004-07-17 HR HR20070552T patent/HRP20070552T3/xx unknown
- 2004-07-17 DE DE602004009195T patent/DE602004009195T2/de not_active Expired - Lifetime
- 2004-07-21 TW TW093121764A patent/TW200524614A/zh unknown
- 2004-07-22 US US10/896,494 patent/US7235547B2/en not_active Expired - Fee Related
- 2004-07-22 AR ARP040102592A patent/AR045926A1/es not_active Application Discontinuation
- 2004-07-23 MY MYPI20042981A patent/MY138394A/en unknown
-
2006
- 2006-01-12 IL IL173131A patent/IL173131A/en not_active IP Right Cessation
- 2006-01-20 NO NO20060328A patent/NO20060328L/no not_active Application Discontinuation
- 2006-01-24 CO CO06006378A patent/CO5640124A2/es not_active Application Discontinuation
- 2006-01-24 ZA ZA200600693A patent/ZA200600693B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5640124A2 (es) | Combinacion de un antagonista de mglur2 y un inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos | |
| AR038481A1 (es) | Derivados de dihidrobenzodiazepin-2-ona iii para el tratamiento de desordenes neurologicos | |
| MXPA05007352A (es) | Compuestos triciclicos inhibidores de proteina quinasa para mejorar la eficacia de agentes antineoplasicos y terapia de radiacion. | |
| DE60320012D1 (de) | Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen | |
| CA2545427A1 (en) | Selective kinase inhibitors | |
| PL406680A1 (pl) | Inhibitory kinaz tyrozynowych | |
| UA84878C2 (ru) | Производные 2-пиридона как ингибиторы нейтрофилов эластазы, фармацевтическая композиция на их основе, способ их получения | |
| ATE446752T1 (de) | Hemmer der akt aktivität | |
| WO2001055116A3 (en) | Quinoline derivatives and their use as aurora 2 kinase inhibitors | |
| MY143400A (en) | 2-pyridone derivatives as neutrophil elastase inhibitors and their use | |
| DE60322359D1 (de) | Imidazopyridinderivate als kinaseinhibitoren | |
| AR042956A1 (es) | Inhibidores de girasa y usos de los mismos | |
| YU84603A (sh) | Novi inhibitori tirozin kinaze | |
| ATE461179T1 (de) | Hemmer der akt aktivität | |
| CA2519898A1 (en) | Oral administration of cyclic protein tyrosine kinase inhibitors | |
| ATE512957T1 (de) | Hemmer der akt aktivität | |
| WO2004071440A3 (en) | Thiazolyl-based compounds useful as kinase inhibitors | |
| RU2011127451A (ru) | ПРОИЗВОДНЫЕ ТИЕНО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ РАКА | |
| IL189003A0 (en) | Methods for treating substance-related disorders | |
| ECSP024403A (es) | Derivados de sulfonil-pirrolidina utiles para el tratamiento de desordenes neurologicos | |
| SE0302324D0 (sv) | Novel compounds | |
| DE60324544D1 (de) | Muskarin antagonisten | |
| SE0302323D0 (sv) | Novel compounds | |
| RU97109847A (ru) | Производные аминотетразола, полезные как ингибиторы синтазы оксида азота | |
| AR037620A1 (es) | 4-feniltetrahidroisoquinolinas sustituidas, procedimientos para su preparacion, su utilizacion como medicamento y medicamento que las contiene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |